Amicus Therapeutics acquires portfolio of gene therapies targeting neurologic disorders

Source: Eric Piermont/AFP/Getty Images

Amicus Therapeutics is expanding the focus its drug development work with the purchase of a portfolio of early-stage gene therapies targeting rare neurologic diseases, the company announced Thursday.

Two of the 10 gene therapies programs being acquired by Amicus have already entered human clinical trials as potential, one-time cures for different forms

You're reading a preview, sign up to read more.

More from STAT

STAT1 min readTech
Listen: Google’s Data Grab, Problematic Genetic Testing, & The Perils Of Biotech Twitter
Do you trust Google with your health data? Is “Gattaca” an outdated reference? And what’s it like to get dunked on? We discuss all that and more on the latest episode of “The Readout LOUD,” STAT’s biotech podcast. First, we dive into the news that Go
STAT2 min readSociety
Apple Launches Virtual Health Studies Aiming To Enroll Hundreds Of Thousands Of Customers
Apple on Thursday launched three health studies — focused on mobility, menstruation, and hearing — that aim monitor hundreds of thousands of people via their own iPhones and Apple Watches.
STAT3 min readSociety
CDC Report: 35,000 Americans Die Of Antibiotic-resistant Infections Each Year
An estimated 35,000 Americans die of antibiotic-resistant infections each year — one every 15 minutes, according to a stark new report released by the CDC.